Abstract
Epidemiologic data support the notion that first-generation high-dose oral contraceptives (containing > 80 micrograms of estrogen) increased the incidence of thromboembolic events. The quantitative interpretation of these data is difficult because results were often confounded by life-style factors and inadequate diagnostic procedures. With the introduction of modern low-dose combination oral contraceptives, the incidence of thromboembolic events decreased markedly. Although all combined oral contraceptives induce statistically significant changes in hemostatic factors, these changes are generally within normal ranges, and their clinical significance is questionable. Overall, increased activity in hemostatic mechanisms appears to remain in balance. Progestin-only formulations seem to affect hemostatic parameters to a much lesser degree, and their use has not led to an increased risk of thrombosis. Interindividual variations in pharmacokinetics and pharmacodynamics of contraceptive steroids are great and could tentatively explain why certain persons may be at an increased risk of thrombosis. Although most studies have looked at steady-state conditions during contraceptive steroid intake, it would seem prudent to investigate further the hemostatic system during a non-steady-state condition, such as that occurring during the first few days of the pill-free interval.
TY - JOUR
T1 - Coagulation and anticoagulation effects of contraceptive steroids.
A1 - Samsioe,G,
PY - 1994/5/1/pubmed
PY - 1994/5/1/medline
PY - 1994/5/1/entrez
KW - Biology
KW - Blood Coagulation Effects
KW - Contraception
KW - Contraceptive Agents
KW - Contraceptive Agents, Female--pharmacodynamics
KW - Contraceptive Agents, Progestin
KW - Contraceptive Agents--pharmacodynamics
KW - Contraceptive Methods
KW - Diseases
KW - Embolism
KW - Family Planning
KW - Hematological Effects
KW - Hemic System
KW - Literature Review
KW - Oral Contraceptives
KW - Oral Contraceptives, Combined
KW - Physiology
KW - Progestins, Low-dose
KW - Thromboembolism
KW - Thrombosis
KW - Vascular Diseases
SP - 1523
EP - 7
JF - American journal of obstetrics and gynecology
JO - Am J Obstet Gynecol
VL - 170
IS - 5 Pt 2
N2 - Epidemiologic data support the notion that first-generation high-dose oral contraceptives (containing > 80 micrograms of estrogen) increased the incidence of thromboembolic events. The quantitative interpretation of these data is difficult because results were often confounded by life-style factors and inadequate diagnostic procedures. With the introduction of modern low-dose combination oral contraceptives, the incidence of thromboembolic events decreased markedly. Although all combined oral contraceptives induce statistically significant changes in hemostatic factors, these changes are generally within normal ranges, and their clinical significance is questionable. Overall, increased activity in hemostatic mechanisms appears to remain in balance. Progestin-only formulations seem to affect hemostatic parameters to a much lesser degree, and their use has not led to an increased risk of thrombosis. Interindividual variations in pharmacokinetics and pharmacodynamics of contraceptive steroids are great and could tentatively explain why certain persons may be at an increased risk of thrombosis. Although most studies have looked at steady-state conditions during contraceptive steroid intake, it would seem prudent to investigate further the hemostatic system during a non-steady-state condition, such as that occurring during the first few days of the pill-free interval.
SN - 0002-9378
UR - https://www.unboundmedicine.com/medline/citation/8178901/Coagulation_and_anticoagulation_effects_of_contraceptive_steroids_
L2 - https://linkinghub.elsevier.com/retrieve/pii/a54049
DB - PRIME
DP - Unbound Medicine
ER -
